Cyclacel Pharmaceuticals Preferred Stock Revenue
| CYCCP Preferred Stock | USD 6.94 0.33 4.99% |
Cyclacel Pharmaceuticals fundamentals help investors to digest information that contributes to Cyclacel Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cyclacel Preferred Stock. The fundamental analysis module provides a way to measure Cyclacel Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclacel Pharmaceuticals preferred stock.
Cyclacel |
Cyclacel Pharmaceuticals Company Revenue Analysis
Cyclacel Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Cyclacel Pharmaceuticals reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States preferred stocks is 100.0% higher than that of the company.
Cyclacel Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclacel Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the preferred stocks which would be a good addition to a portfolio. Peer analysis of Cyclacel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cyclacel Pharmaceuticals by comparing valuation metrics of similar companies.Cyclacel Pharmaceuticals is currently under evaluation in revenue category among its peers.
Cyclacel Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cyclacel Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cyclacel Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Cyclacel Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 24.42 M | ||||
| Shares Outstanding | 12.5 M | ||||
| Shares Owned By Insiders | 0.47 % | ||||
| Price To Earning | (2.62) X | ||||
| Gross Profit | (338 K) | ||||
| EBITDA | (15 M) | ||||
| Net Income | (18.89 M) | ||||
| Cash And Equivalents | 29.08 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 113 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 6.38 X | ||||
| Book Value Per Share | 1.76 X | ||||
| Cash Flow From Operations | (18.54 M) | ||||
| Earnings Per Share | (2.05) X | ||||
| Number Of Employees | 14 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 23.14 M | ||||
| Total Asset | 42.59 M | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 9.20 % | ||||
| Net Asset | 42.59 M |
About Cyclacel Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclacel Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclacel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclacel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cyclacel Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclacel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Cyclacel Preferred Stock
Moving against Cyclacel Preferred Stock
| 0.69 | GRCE | Grace Therapeutics, Symbol Change | PairCorr |
| 0.59 | ZBIO | Zenas BioPharma, Common Downward Rally | PairCorr |
| 0.32 | FRTX | Fresh Tracks Therapeutics | PairCorr |
The ability to find closely correlated positions to Cyclacel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclacel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclacel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclacel Pharmaceuticals to buy it.
The correlation of Cyclacel Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclacel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclacel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclacel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cyclacel Preferred Stock Analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.